Efficacy and Tolerability of Clarema 1% Cream and Hirudoid 40000 U.APTT Gel in the Topical Treatment of Haematomas and/or Subcutaneous Haematic Extravasations

Table 2

Subjective symptoms and objective signs of haematomas/extravasations (secondary efficacy variables).

(a)

Parameter	Mean decrease from baseline to endpoint
	Mean [95% CI]		Differences between the adjusted means [95% CI]
	Heparan sulfate	GAGPS
Pain at rest	−1.2 [−1.4 to −1.1]	−1.1 [−1.3 to −1.0]	0.02 [0.07 to 0.11]
Pain on movement	−1.9 [−2.0 to −1.7]	−1.4 [−1.6 to −1.1]	0.53 [0.27 to 0.78]
Functional disability	−1.6 [−1.8 to −1.4]	−1.3 [−1.5 to −1.1]	0.39 [0.09 to 0.68]
Oedema	−2.3 [−2.5 to −2.1]	−1.9 [−2.2 to −1.7]	0.41 [0.19 to 0.63]
Colour of the lesion	−2.8 [−2.9 to −2.7]	−2.1 [−2.3 to −2.0]	0.64 [0.42 to 0.87]
Size of the lesion
Minimum diameter	−5.1 [−5.8 to −4.5]	−3.9 [−4.6 to −3.2]	1.48 [0.88 to 2.08]
Maximum diameter	−8.0 [−8.8 to −7.2]	−5.9 [−6.9 to −4.8]	2.25 [1.37 to 3.14]
Product of min*max diameter	−50.5 [−59.5 to −41.5]	−50.2 [−65.9 to −34.6]	5.95 [1.35 to 10.56]

(b)

Parameter	Complete disappearance
	𝑛 (%)		Fisher’s exact test
	Heparan sulfate	GAGPS
Pain at rest	46 (95.8)	45 (93.8)	NS
Pain on movement	30 (62.5)	11 (22.9)	<0.0001
Functional disability	30 (62.5)	15 (31.3)	0.0015
Oedema	43 (89.6)	28 (58.3)	<0.0001
Colour of the lesion	38 (79.2)	15 (31.3)	<0.0001